Inici › Càncer de bufeta › Illinois › Chicago
Assaigs clínics de Càncer de bufeta a Chicago, IL
21 estudis de Càncer de bufeta busquen participants en centres de Chicago i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
ReclutantFase 1
- University of Chicago Hospital, Chicago
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
ReclutantFase 1/2
- University of Chicago Medical Center ( Site 5037), Chicago
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
ReclutantFase 3
- Northwestern University, Chicago
- University of Illinois, Chicago
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ReclutantEstudi observacionalVoluntaris sans benvinguts
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- i 1 més
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
ReclutantFase 2
- Rush MD Anderson Cancer Center, Chicago
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
ReclutantFase 2
- University of Illinois Cancer Center, Chicago
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
ReclutantFase 2
- Northwestern University, Chicago
- Northwestern Medicine Cancer Center Old Irving Park, Chicago
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
ReclutantFase 2
- Rush MD Anderson Cancer Center, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
ReclutantFase 1
- Northwestern Memorial Hospital, Chicago
- Northwestern University - Feinberg School of Medicine, Chicago
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
ReclutantFase 3
- University of Illinois at Chicago, Chicago
- University of Chicago Medical Center, Chicago
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
ReclutantFase 1
- The University of Chicago Medical Center (UCMC), Chicago
Measuring Surgical Recovery After Radical Cystectomy
ReclutantEstudi observacional
- University of Chicago, Chicago
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
ReclutantFase 3
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
ReclutantFase 2
- UChicago Medicine - River East, Chicago
- University of Chicago Medical Center, Chicago
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
ReclutantFase 1
- UChicago Medicine - River East, Chicago
- The University Of Chicago, Chicago
- University of Chicago Medical Center, Chicago
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors
ReclutantFase 2
- Northwestern University, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
ReclutantFase 1
- The University of Chicago Comprehensive Cancer Center, Chicago
Blue Light Cystoscopy With Cysview® Registry
ReclutantEstudi observacional
- Northwestern University, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutantEstudi observacional
- Massive Bio SYNERGY-AI site, Chicago
Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer
ReclutantEstudi observacional
- Jesse Brown Department Of Veterans Affairs Medical Center, Chicago
Comprehensive Geriatric Assessment (Tests) for Bladder Cancer Participants Undergoing Radical Cystectomy
Reclutant
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Assaigs de Càncer de bufeta en altres ciutats
- New York City, NY35 estudis
- Nashville, TN31 estudis
- Houston, TX31 estudis
- Dallas, TX27 estudis
- Boston, MA26 estudis
- Washington, DC26 estudis
- Los Angeles, CA24 estudis
- Baltimore, MD24 estudis
- St. Louis, MO22 estudis
- Philadelphia, PA21 estudis
- Seattle, WA21 estudis
- Edison, NJ21 estudis
Altres estudis a Chicago
- Càncer de pulmó de cèl·lules no petites61 estudis
- Càncer de mama58 estudis
- Càncer (tots els tipus)51 estudis
- Càncer metastàtic45 estudis
- Càncer de pròstata45 estudis
- Obesitat41 estudis
- Càncer de pulmó41 estudis
- Càncer d'ovari36 estudis
- Ictus34 estudis
- Càncer colorrectal33 estudis
- Insuficiència cardíaca31 estudis
- Sobrepès28 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.